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It is estimated that at least 26 million people are suffering from schizophrenia worldwide.\[[@ref1]\] Second-generation antipsychotics (SGA) have largely replaced conventional antipsychotics for the treatment of behavioral disorders such as schizophrenia, bipolar disorder, and autism due to their modest therapeutic efficacy and better safety profile.\[[@ref2]\] Therapeutic efficacy of atypical antipsychotics varies from drug to drug in different individuals.\[[@ref3]\] Risperidone is one of the well-established SGA and widely used in the treatment of schizophrenia.\[[@ref4]\] It has a combined antagonist effects for dopamine (*DRD2*) and serotonin (*5HTR2A*, *2C*) receptors. *DRD2* and 5HTR2 neurotransmission are the major pathways involved in the disease pathophysiology as well as symptom improvement and drug-induced extrapyramidal symptoms (EPSs) in schizophrenia.\[[@ref5][@ref6]\] When compared to conventional antipsychotic drugs, it has greater efficacy in symptom amelioration and less severe adverse effects. Several studies have reported high prevalence of risperidone-associated adverse effects such as hyperprolactinemia, weight gain, EPSs, and other adverse effects in patients with schizophrenia.\[[@ref7][@ref8][@ref9][@ref10]\] These adverse effects may lead to other secondary complications such as metabolic syndrome, diabetes mellitus, sexual dysfunction, and cardiac problems in patients suffering from schizophrenia which can reduce their quality of life.\[[@ref11]\]

Several studies have suggested that polymorphism in dopamine and serotonin receptors was associated with reduced receptor density which may play an important role in drug efficacy and drug-induced adverse effects.\[[@ref12][@ref13][@ref14]\] Recently, a study by Zhang *et al*. reported the importance of *DRD2* − 141 C Ins/Del polymorphism in antipsychotic (any one of the five antipsychotics) response and associated adverse effects in Chinese population (thirty patients received risperidone) and shown a significant association.\[[@ref15]\] Similarly, other studies reported the role of serotonin receptor polymorphism *5HTR2C* (−759 C\>T) in antipsychotic-induced weight gain, prolactin increase, and EPSs.\[[@ref16][@ref17][@ref18]\] Due to limited data and involvement of various antipsychotics, none of the studies have established genetic polymorphisms as biomarkers in the clinical setting. Although several studies have reported the adverse effects of risperidone, very few studies reported related adverse effects with genetic variants to dopamine and serotonin receptor in the Indian population.\[[@ref19][@ref20]\] Since it is likely that *DRD2* polymorphism can affect the EPS and *5HTR2C* polymorphism in food intake the present study was aimed to investigate the safety profile of risperidone and the role of genetic variants *DRD2* (−141 C Ins/Del/rs1799732) and *5HTR2C* (−759 C\>T/rs3813929).
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The study was conducted among 289 schizophrenic patients diagnosed as per Diagnostic and Statistical Manual of Mental Disorders, 4^th^ Edition, Text Revision criteria during December 2013--August 2015. Patients were either prescribed risperidone (subgroup) or on risperidone for 4 weeks or more. The study was approved by the Institute Ethics Committee, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. Patients were recruited from Psychiatry Outpatient Department, JIPMER. After explaining the study procedure, informed consent was obtained from all the patients or their legally acceptable representatives. The study participants were on treatment with risperidone (4--8 mg/day) for a minimum of 4 or more weeks. Patients who had a history of medical illness or substance abuse, pregnant women, nursing women, and with age of \<18 years were excluded from the study.

Five milliliter of blood was collected from each patient to study the genetic polymorphisms *DRD2* (−141 C Ins/Del) and *5HTR2C* (−769 C\>T). DNA was extracted from leukocyte by standard phenol-chloroform method. Genotyping for *DRD2* (−141 C Ins/Del) and *5HTR2C* (−759 C\>T) genes were performed on real-time thermocycler (ABI Prism 7300) using Taqman SNP probe (rs1799732, Catalog No. 4331349, Assay ID: 0150250174; rs3813929 Catalog No. 4351379 Assay ID: C_27488117_10 Applied Biosystems, Foster City, CA, USA). All the patients were evaluated for adverse drug reactions (ADRs) after 4 or more weeks of the study period. Changes in prolactin levels and body weight were analyzed for a subgroup of patients for whom the baseline values before start of risperidone was available. Serum prolactin levels were measured by using Advia Centaur^®^ Chemiluminescence Immunoassay Kit code 10309975 (Advia-Centaur CP, Siemens healthcare diagnostics, Germany).\[[@ref21]\] After 4 weeks of risperidone therapy, patients showing \>20% increase in prolactin levels from baseline were considered to have developed hyperprolactinemia.\[[@ref22]\] Weight assessment was done at baseline and after taking risperidone (4--8 mg/day) for 6 weeks. An increase of \>5% weight gain in 6 weeks was considered significant.\[[@ref23][@ref24]\] The ADRs were classified as per Naranjo algorithm score into four categories, i.e., definite, probable, possible, and doubtful ADRs.\[[@ref25]\]
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Demographic parameters were expressed as mean ± standard deviation. ADRs were analyzed descriptively. Associations between genetic variants, prolactin levels, weight gain, and EPS were analyzed using SNP Stats software (Institut Català d'Oncologia, Barcelona, Spain). Genotype frequencies were assessed for Hardy--Weinberg equilibrium. Correlation between prolactin levels and weight gain were analyzed using Spearman Rank correlation SPSS version 19.0 (IBM -- SPSS, Inc., 2009, Chicago, IL, USA) Fisher\'s test was used to see the association between prolactin levels and EPS using GraphPad InStat software (version 3.06, 32 bit for Windows, September 11, 2003, GraphPad Software, San Diego California USA).
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Demographic characteristics of schizophrenic patients receiving a mean dose of risperidone 4.5 mg/day (4--8 mg/day) are given in [Table 1](#T1){ref-type="table"}.

###### 

Demographic characteristics (*n*=289)

![](JPP-8-28-g001)

Among 289 patients, 197 experienced at least 1 ADR (68.2%). Fifty patients experienced only 1 ADR whereas others experienced 2 or more ADRs such as tremors, rigidity, akathisia, tardive dyskinesia, sedation, hyperprolactinemia, and weight gain.

We could estimate the changes in prolactin levels in 102 (59 male/43 female) and weight in 97 (58 male/39 female) patients. Changes observed in these two parameters and other ADRs are shown in [Table 2](#T2){ref-type="table"}.

###### 

Adverse drug reactions associated with risperidone-based therapy
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Causality analysis by Naranjo\'s algorithm of all the 353 ADRs to risperidone-based therapy showed that 92.6% (327/353) ADRs were having score of 5--8 and belonged to the probable category and 7.4% (26/353) were having score of 1--4 and belong to the possible category. None belongs to the definite or doubtful category. When compared the genotype frequency of *5HTR2C* −759 C\>T polymorphism of schizophrenia patients \[Supplementary Table 1\] and healthy individuals from the South India (*n* = 96 \[71 male/25 female\], CC = 0.5, CT = 0.21, TT = 0.23; odds ratio \[OR\] = 0.52; 95% confidence interval \[CI\] = 0.30--0.92; *P* = 0.074) we did not find significant difference in polymorphism distribution.

###### 

Genotype frequencies (*n*=289)

###### 

Click here for additional data file.

*DRD2* gene −141C Ins/del polymorphism did not show any association with risperidone-based therapy induced EPSs (*n* = 99, OR = 0.68, 95% CI = 0.30--1.52, *P* = 0.3) and similarly *5HTR2C* gene −759 C\>T polymorphism was not associated with EPSs (*n* = 105, OR = 0.57, 95% CI = 0.20--1.58, *P* = 0.2). Association analysis of genotypes with hyperprolactinemia and weight gain is shown in [Table 3](#T3){ref-type="table"} and Supplementary Table 2.

###### 

Association between *DRD2* −141 C Ins/Del and *5HT2C* (−759 C\>T) genetic variants and risperidone-induced increase in prolactin levels
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###### 

Association between *DRD2* −141 C Ins/Del or *5HT2C* (−759 C\>T) genetic variants and risperidone induced weight gain

###### 

Click here for additional data file.

Serum prolactin levels increased from baseline to follow-up (33.21 ± 29.94--71.44 ± 51.99 \[ng/ml\], *n* = 102, *P* \< 0.01), and weight change was observed from baseline to follow-up (55.9 ± 12.92--61.8 ± 13.50 \[kg\], *n* = 97, *P* = 0.02). After the follow-up period, we have found the weak positive correlation (*n* = 92, *r* = 0.3, *P* = 0.005) between percentage increase in serum prolactin levels and percentage increase in weight gains. EPSs were seen in 40/102 patients, and we did not find any association with increased prolactin levels (*n* = 102, OR = 0.96, 95% CI = 0.2--3.1, *P* = 1.0).
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In the present study, we have studied the adverse effects of risperidone-based therapy in patients with schizophrenia and the role of *DRD2* − 141C Ins/Del and *5HTR2C* −759 C\>T genetic polymorphisms in the causation of weight gain and hyperprolactinemia, along with EPS.

Although several studies have tried to explain the role of pharmacogenetic factors influencing the adverse effects of other antipsychotic drugs, very few studies are available with respect to risperidone-based therapy. In the present study, risperidone-induced hyperprolactinemia was observed in 87.2% of the patients, and we have found a significant association of −141 C deletion with the risk of increase in prolactin levels. There are few studies which have shown the elevated prolactin levels to be a marker for risperidone response, but our previous study found a nonsignificant difference in prolactin elevation between responders and nonresponders.\[[@ref22]\]

Hyperprolactinemia-related adverse effects such as amenorrhea and galactorrhea were observed in 6.1% and 1.7% in female patients, respectively. Available evidence shows that therapeutic doses of first-generation antipsychotics can cause a tenfold increase in prolactin levels when compared to SGA.\[[@ref26]\] Our study findings are consistent with the previous study by Zhang *et al*. They have reported the association of *DRD2* (Taq1A; −141 C Ins/Del) gene polymorphism with elevated prolactin levels in Chinese patients on antipsychotic medication.\[[@ref15]\] A recent study by Sukasem *et al*. reported the *DRD2* (Taq1A) variants association with elevated prolactin levels, and Zhang *et al*. reported that *DRD2* polymorphism (rs2514218) is associated with positive symptom improvement and prolactin elevation with risperidone therapy in male patients with first-episode psychosis.\[[@ref27][@ref28]\] However, Calarge *et al*. reported no association between *DRD2* (−141 C Ins/Del) polymorphism and prolactin levels on risperidone treatment in non-Hispanic Caucasians population.\[[@ref13]\] Similarly, other studies by Nagai *et al*. and Yasui-Furukori *et al*. also reported no association between *DRD2* polymorphism and prolactin levels in the Japanese population.\[[@ref29][@ref30]\] These differences may be attributed to other factors responsible for variation of single point prolactin levels such as age, food habits, menstrual cycle, exercise, and stress that can vary with geographical location and ethnicities.\[[@ref31]\] Weight gain was observed in 53.6% of the patients. It has been reported that benzodiazepines do not cause weight loss; hence, their concomitant use has not contributed in weight gain.\[[@ref32][@ref33]\] Several studies have suggested that *5HTR2C* receptor is a candidate gene for antipsychotic drug-induced weight gain which has an important role in feeding behavior. It has been proposed that risperidone-induced central inhibition of *5HTR2C* receptors increases food intake in spite of satiety, resulting in weight gain.\[[@ref34]\] Genetic variant in the promoter region of 5HT2C receptor gene (−759 C\>T) has been commonly studied in association with antipsychotic drug-induced weight gain in different populations. However, there were no studies in the Indian population. A study by Hoekstra *et al*. in Dutch children and adolescents with autism spectrum disorders demonstrated a reduced risk of antipsychotic drug-induced weight gain among carriers of T allele of *5HTR2C* −759 C\>T polymorphism.\[[@ref35]\] However, the present study did not find any association between *5HTR2C* (−759 C\>T)/*DRD2* (−141 C Ins/Del) gene polymorphisms and weight gain due to risperidone-based therapy. Our study findings are in contrast to previous study Reynolds *et al*. in Han Chinese patients.\[[@ref18][@ref36]\] However, the frequency of weight gain (53.6%) in the study is higher than earlier study by Almoguera *et al*. (36%).\[[@ref37]\] Available literature says that hyperprolactinemia can also induce the weight gain by decreasing insulin sensitivity and by producing an imbalance in gonadal hormones.\[[@ref36]\] Early and rapid weight gain in the initial stages of therapy is a predictor of long-term weight gain due to antipsychotics.\[[@ref38]\]

Earlier studies have reported a weak positive correlation between prolactin levels and weight gain.\[[@ref39]\] However in the present study, we found a weak positive correlation (*r* = 0.3) between increase in prolactin levels and increase in weight gain. Moreover prospective studies with larger sample size are required to draw a strong conclusion.

Drug-induced EPS are other important adverse effects of risperidone. Tremors are the most frequent EPS in the present study (86.8%) despite the fact that 63% of patients got trihexyphenidyl. Akathisia and rigidity accounted for 18.9% and 13.2% of EPS, respectively. This was similar to the study by Almoguera *et al*. (2013) in Spanish patients, where EPS was found to occur at a frequency of 36%. However, the frequency of EPS observed in our study is slightly higher than that observed in a multicenter, randomized controlled trial (32.8%, *n* = 111) in Chinese patients.\[[@ref40]\] A recent study by Mas *et al*. (2016) reported higher frequency (41%) of risperidone-induced EPS in Spanish patients with a first psychotic episode.\[[@ref41]\] Further, based on a systematic review, risperidone was associated with more incidences of EPS than clozapine, olanzapine, quetiapine, and ziprasidone.

This is the first study to report adverse effects of risperidone-based therapy in relation with genetic variants of *DRD2* and 5HT2C in South Indian patients with schizophrenia. Limitation of our study is masking of EPS due to simultaneous prescription of trihexyphenidyl.
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Hyperprolactinemia, weight gain, and EPSs were the common ADRs among schizophrenic patients treated with risperidone. *DRD2* − 141 C Ins/Del genetic variant was significantly associated with increase in prolactin levels. A weak positive correlation was observed between percentage increase in prolactin levels and weight gain. The study could not detect a significant association between *5HTR2C* −759 C\>T gene polymorphism and risperidone-induced weight gain.
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